di Biase Lazzaro, Pecoraro Pasquale Maria, Carbone Simona Paola, Di Lazzaro Vincenzo
Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128, Rome, Italy.
Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, Rome, 21 - 00128, Italy.
Neurol Sci. 2025 Jul;46(7):3117-3126. doi: 10.1007/s10072-025-08112-y. Epub 2025 Mar 21.
Uric acid has been supposed to have a protective role in Parkinson's disease with controversial findings. This relationship has not been validated with pathology-confirmed diagnoses. This study aims to compare uric acid levels between pathology-confirmed and clinically-misdiagnosed Parkinson's disease patients over time.
65 patients with an in-vivo clinical diagnosis of Parkinson's disease were enrolled from the UK Brain Bank. 33 were confirmed with post-mortem pathology analysis, while 32 were clinically misdiagnosed patients. Chart review explored uric acid levels at two timepoints (NO and N1). A repeated-measures ANOVA evaluated uric acid level variation over time and determined differences between the groups, including timespan between samples, disease duration, age at death, age of onset and sex as covariates.
Average uric acid levels at N0 were 5.83 mg/dl (SD ± 1.99) and 5.94 mg/dl (SD ± 1.87) for respectively true and false positives. At N1, the values were 7.61 mg/dl (SD ± 2.35) and 7.36 mg/dl (SD ± 2.86) for respectively true and false positives. A significant main effect of time on uric acid levels was found (F(1, 58) = 4.303, p = 0.042, η_p = 0.069). The interaction between time and the covariates was not significant, suggesting that these variables did not influence uric acid level variation over time. No influence of the diagnostic confirmation and covariates on uric acid levels between groups was found.
While uric acid levels increase over time in Parkinson's disease patients, this increase does not differ significantly between those with confirmed and unconfirmed diagnoses, nor it is influenced by disease duration, age at death, age of onset or sex.
尿酸在帕金森病中被认为具有保护作用，但其研究结果存在争议。这种关系尚未通过病理确诊得到验证。本研究旨在比较经病理确诊和临床误诊的帕金森病患者随时间变化的尿酸水平。
从英国脑库招募了65例临床诊断为帕金森病的患者。其中33例经尸检病理分析确诊，32例为临床误诊患者。通过病历回顾探究了两个时间点（NO和N1）的尿酸水平。采用重复测量方差分析评估尿酸水平随时间的变化，并确定两组之间的差异，将样本采集时间间隔、病程、死亡年龄、发病年龄和性别作为协变量。
N0时，真阳性和假阳性的平均尿酸水平分别为5.83mg/dl（标准差±1.99）和5.94mg/dl（标准差±1.87）。在N1时，真阳性和假阳性的值分别为7.61mg/dl（标准差±2.35）和7.36mg/dl（标准差±2.86）。发现时间对尿酸水平有显著的主效应（F(1, 58)=4.303，p=0.042，η_p=0.069）。时间与协变量之间的交互作用不显著，表明这些变量不影响尿酸水平随时间的变化。未发现诊断确认和协变量对两组之间尿酸水平有影响。
虽然帕金森病患者的尿酸水平随时间升高，但在确诊和未确诊的患者中，这种升高没有显著差异，也不受病程、死亡年龄、发病年龄或性别的影响。
